Leo Holdings Corp. (LHC), which is headed for an extension vote on February 11th, filed an 8-K this morning providing information on a potential target they are in discussions with for a combination. These were termed “advanced discussions”, but it sounds like regardless of how far along they are in the process, they won’t be able to get a definitive agreement on file ahead of their shareholder vote to extend. As such, they are only able to provide some headline details about the company.
Those headline details are that this is a “high-growth, technology-enabled business capitalizing on the secular shift of advertising dollars from traditional offline channels to online digital channels by helping connect consumers and advertisers with innovative marketplace solutions. Leo believes that the target’s financial profile is compelling with significant historical revenue growth, expected revenue growth for 2020 of 30% and strong EBITDA margins and cash conversion.” Additionally, the EV/EBITDA multiple is expected to be 13 time fiscal year 2020 expected EBITDA.
So what can we glean from this new information. For one, it sounds like Leo Holdings Corp. would like to hang on to their cash in trust, otherwise they wouldn’t have put this information out hoping to pique the interest of investors. If you recall, LHC is not offering any contribution to trust for non-redeeming shareholders and they are asking for an additional five and a half months. Typically in those situations, no contribution and a long extension means a SPAC is either trying to reduce their trust value to accommodate a smaller than anticipated target, or they want to replace the cash in trust with a PIPE. However, in LHC’s case, by providing detail on a pending announcement ahead of their vote, they’re trying to signal “you should reconsider if you were planning on redeeming”. Nebula was facing similar circumstances, but managed to squeak in their transaction announcement a few days ahead of their extension vote.
However, there’s no guarantee that these advanced talks will lead to a definitive agreement, so it’s a bit of a risk for investors. Plus, without being able to drill down on all the details, it’s hard to say if LHC’s deal will be a real winner. Or, if there’s a PIPE involved and at we don’t know at what price. However, the 8-K certainly is intriguing. The question is, is it intriguing enough to protect their cash in trust? We have two weeks to find out, but maybe LHC will manage to move the discussions far enough along that we get a real announcement ahead of their vote.


FIGX Acquisition Corp. (NASDAQ:FIGXU) announced the pricing of its $131 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “FIGXU”, Friday, June 27, 2025. The new SPAC aims to seek out a financial services target with a particular focus on wealth and asset managers with the potential to...
Yorkville Acquisition Corp. (NASDAQ:YORKU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “YORKU”, Friday, June 27, 2025. The new SPAC plans to combine with a target company in the telecom, media or technology sectors. Yorkville Acquisition Corp.’s management team is led...
At the SPAC of Dawn As pressure on Fed Chairman Jerome Powell increases, the market is set to ingest a raft of new indicators today as well as hear from Cleveland Fed President Beth Hammack on the potential interest rate path. Today will also see June’s 8th SPAC IPO as Cantor Equity Partners III Inc....
Cantor Equity Partners III Inc. (NASDAQ:CAEP) announced the pricing of its upsized $240 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “CAEP”, Thursday, June 26, 2025. The new SPAC plans to combine with a target company in an industry where its management has relevant expertise such financial...
Launch One (NASDAQ:LPAA) has entered into a definitive agreement to combine with biotech firm Minovia Therapeutics at a $180 million pre-money valuation. Haifa, Israel-based Minovia is developing a drug platform based on mitochondrial cell therapies to potentially treat rare disorders as well as the effects of aging and other causes of bodily degeneration. The combined...